Cancer Research Annual Meeting 2010  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 33, 256-261, February 1, 1973]
© 1973 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldberg, A. I.
Right arrow Articles by Milman, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldberg, A. I.
Right arrow Articles by Milman, H. A.

The Effects of Immunization of L-Asparaginase on Antitumor and Enzymatic Activity

Arthur I. Goldberg, David A. Cooney, John P. Glynn1, Elton R. Homan, Marilyn R. Gaston and Harry A. Milman

Drug Evaluation Branch, Drug Research and Development [A. I. G., J. P. G., M. R. G.], and Laboratory of Toxicology, Experimental Therapeutics [D. A. C., E. R. H., H. A. M.], Chemotherapy, National Cancer Institute, Bethesda, Maryland 20014

BALB/c mice were immunized with Escherichia coli L-asparaginase and tested for the presence of hemagglutination antibody (HA) to the enzyme. Mice were then grouped according to whether they were immune to L-asparaginase (HA titer, >4) or were non-HA responders (negative HA titer). In vivo antitumor activity of L-asparaginase against P-1798 (an L-asparaginase-sensitive lymphoma) was tested in both groups, as well as in control mice (never before exposed to L-asparaginase). L-Asparaginase was inactive against the tumor in immune mice but was equally active in non-HA responders and control animals. Another experiment compared L-asparaginase derived from E. coli with enzyme derived from Erwinia carotovora (which does not cross-react immunologically with E. coli L-asparaginase). Mice immune to E. coli L-asparaginase received about the same benefit from the antitumor activity of E. carotovora L-asparaginase as did control mice. In separate studies, blood samples from immune, non-HA responder, and control mice were tested by in vitro assays for levels of L-asparaginase and L-asparagine at various time intervals up to 120 hr following a single i.v. injection of L-asparaginase. Most immune mice cleared the plasma of enzyme 30 min after injection and consequently had a rapid return to the circulation of L-asparagine. In non-HA responders and control animals, L-asparaginase was detectable for over 48 hr after injection, and L-asparagine remained absent from the circulation. These studies relate the presence of humoral antibody to L-asparaginase with loss of antitumor and enzymatic activity and suggest that, in immunized animals without detectable HA, the antitumor and enzymatic activity of L-asparaginase is intact.

1 Deceased (May 7, 1971).

Received 2/ 4/72. Accepted 10/20/72.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1973 by the American Association for Cancer Research.